LEADER 04232nam 2200637Ia 450 001 9910830979303321 005 20230721004755.0 010 $a1-118-67350-6 010 $a1-282-34938-4 010 $a9786612349386 010 $a0-470-74134-1 035 $a(CKB)1000000000707370 035 $a(EBL)416371 035 $a(OCoLC)313862959 035 $a(SSID)ssj0000112506 035 $a(PQKBManifestationID)11129193 035 $a(PQKBTitleCode)TC0000112506 035 $a(PQKBWorkID)10097330 035 $a(PQKB)11102822 035 $a(MiAaPQ)EBC416371 035 $a(EXLCZ)991000000000707370 100 $a20080915d2008 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aBiotechnology valuation$b[electronic resource] $ean introductory guide /$fKarl D. Keegan 210 $aChichester, England ;$aHoboken, NJ $cJohn Wiley & Sons$dc2008 215 $a1 online resource (220 p.) 225 1 $aWiley finance 300 $aDescription based upon print version of record. 311 $a0-470-51178-8 320 $aIncludes bibliographical references (p. [189]-192) and index. 327 $aBiotechnology Valuation; Contents; Acknowledgements; 1 Introduction; Biotechnology Background; 2 Traditional Valuation Methods; The Value of a Company; Accounts - Providing the Data for Valuation Analysis; The Income Statement; Balance Sheet; Cash Flow Statement; Income Statement Multiples; Balance Sheet Multiples; Summary; Discounted Cash Flow Analysis; Net Present Value; Constructing the DCF; Projecting the Cash Flow Stream; Choosing a Discount Rate; Other Thoughts; 3 The Drug Development Process; The Drug Development Process; Drug Discovery and Research; Pre-Clinical Development 327 $aClinical TrialsWhat Investors Should Look For When Analysing Clinical Trials; Conclusion; The Regulatory Process; Regulation in the US; Regulation in Europe; The Label; Timelines for Approval; Post Approval; Investment Lessons; Case Study #1; 4 Biotechnology Company Valuation; Data Collation; NPV of the Pipeline; Calculations; Sensitivity Analyses; DCF of Whole Company; EBIT DCF of Products; Comparables Valuation; NPVs are Additive; Using all the Tools Available to Reach a Valuation Conclusion; Market Models; Conclusion; Appendix 1; Example 1; Example 2; Example 3; Appendix 2 327 $aBiosimilar Update5 Decision Trees and Real Options; Decision Trees; Discount Rate; Deriving Scenarios; Conclusion; Decision Tree Example; Real Options; Valuing Options; Estimation of the Input Variables; Conclusions; 6 Biotechnology Investing; Types of Healthcare Investment; Biotechnology Sector Evolution; Biotechnology Investment Cycles; Biotechnology Business Models; Focus on People; Cash; Product Pipeline; Commercial Risks; Newsflow; Lessons from Biotech Investing; 7 Early-stage Valuation; Private Valuation; Discounted Cash Flow Method; Comparable Valuation; Venture Capital Method 327 $aDiscount RatesConclusion; Glossary; References; Index 330 $aThe first book to provide a simple and practical means of valuing biotech companiesThe book begins with a short history of the biotechnology industry; this is important as although it is about 30 years old, the first company went public only in 1996, so it is possible to plot the course of investment waves and dipsIt examines the European industry and its evolvement, and draws parallels between the similarities and differences between that and the USLooks at the various companies which make up the biotech industry (therapeutic; life sciences; and the medical 410 0$aWiley finance series. 606 $aBiotechnology industries$xValuation 606 $aPharmaceutical industry$xValuation 606 $aInvestment analysis 615 0$aBiotechnology industries$xValuation. 615 0$aPharmaceutical industry$xValuation. 615 0$aInvestment analysis. 676 $a332.63221 676 $a380.1456606 700 $aKeegan$b Karl D$01683717 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910830979303321 996 $aBiotechnology valuation$94054695 997 $aUNINA